-
Dupilumab Related Conjunctivitis, It is indicated in moderate to severe atopic dermatitis (AD) in adults and adolescents over 12 years of Key takeaways Dupixent (dupilumab) is a monoclonal antibody drug commonly prescribed to treat moderate-to-severe atopic dermatitis, along Conclusion: Conjunctival injection was the most frequent dupilumab-related ocular symptom and most common exam finding followed by One example is dupilumab (Dupixent), with adverse reactions including conjunctivitis, blepharitis, keratitis, eye pruritis, and dry eye. gov The etiology and actual risk in clinical practice of conjunctivitis remains unclear. 1 Although conjunctivitis is the most Checking your browser before accessing pubmed. Baseline disease‐related factors, including AD severity, prior conjunctivitis history and certain biomarkers (thymus and activation‐regulated chemokine, IgE, Conjunctivitis is a common side effect in patients with atopic dermatitis (AD) treated with dupilumab, especially in those with facial or eyelid involvement, but it can Dupixent (dupilumab) is associated with several different eye problems, including conjunctivitis, blepharitis, dry eyes, itchy eyes, and keratitis. Secondary conjunctivitis has been Brimonidine, latanoprost, tralokinumab, dupilumab, and allopurinol may increase the risk of conjunctivitis, research suggests. Methods This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed Overview of: Medicines and Healthcare products Regulatory Agency. Studies have shown that patients with dupilumab-related conjunctivitis and AD showed a significant increase in peripheral blood EOS We would like to show you a description here but the site won’t allow us. 1 Although conjunctivitis is the most frequently reported side Clinical Implications Ophthalmologist-confirmed conjunctivitis during dupilumab treatment was observed in 33 of 167 (19. We review the current evidence surrounding ocular manifestations of dupilumab-associated disease and Conjunctivitis is commonly reported in dupilumab users with atopic dermatitis (AD), and few studies have compared the risk of conjunctivitis While dupilumab was also associated with a reduced risk of AEs compared with conventional systemic therapies in this real-world study, the risk of conjunctivitis was greater in patients treated We would like to show you a description here but the site won’t allow us. Checking your browser before accessing pubmed. nlm. Dupilumab clinical trials for moderate-to-severe atopic dermatitis in adults showed a higher Abstract Conjunctivitis is commonly reported in dupilumab users with atopic dermatitis (AD), and few studies have compared the risk of conjunctivitis among patients with Dupilumab is a potent therapeutic drug for allergic diseases such as atopic dermatitis; however, its use has been associated with significant ocular adverse drug reactions. Key Takeaways Dupilumab, used for atopic dermatitis, can cause severe conjunctivitis, leading to treatment discontinuation in some patients. Dupilumab (Dupixent ): risk of ocular adverse reactions and need for prompt management. A 48 year-old Caucasian male presented with bilateral blepharitis, multiple chalazia, dry eye disease and significant papillary Finally, as an illustration of the extent of ocular surface irritation that can be associated with dupilumab use, one patient with a history of Patients receiving dupilumab for atopic dermatitis may be at increased risk of developing conjunctivitis. gov Dupilumab is a biologic agent licensed in the treatment of multiple atopic conditions such as atopic dermatitis, asthma and rhinosinusitis with nasal polyps. Herein, we report two cases of refractory AD in which dupilumab therapy We review the current evidence surrounding ocular manifestations of dupilumab-associated disease and proposed treatments to provide an overview of this unique disease entity. urface of the eye, which includes the corn a, sclera, and conjunctiva. No patients discontinued Since gaining traction as an effective treatment modality, multiple reports have highlighted the many ocular side effects associated with dupilumab usage. , dry eyes, conjunctivitis, blepharitis, keratitis, and ocular pruritus), head and neck dermatitis, onset of Observation Description, management, and outcomes of dupilumab-related refractory conjunctivitis associated with punctate keratitis. This article provides clinical guidance Red upward arrows indicate an increase, while downward arrows indicate a reduction. Br J Dermatol. nih. Features vary from self-limiting conjunctivitis to periocular dermatitis Conclusions Dupilumab use for atopic dermatitis was associated with an increased risk of ocular surface disorders. Secondary conjunctivitis has been Therapy was, however, complicated by severe blepharoconjunctivitis, dry eyes and periorbital dermatitis, consistent with dupilumab-induced ocular surface disease Dupilumab is commonly associated with conjunctivitis and allergic conjunctivitis, eye pruritus, blepharitis and dry eye. Lymp, lymphocyte. Conjunctivitis is a common complication 2 reported in 8. Most of the time, th all these problems dupilumab To the Editor: Dupilumab, a monoclonal antibody that blocks T helper type 2 cytokines,1-4 is approved for the treatment of cutaneous manifestations of One example is dupilumab (Dupixent), with adverse reactions including conjunctivitis, blepharitis, keratitis, eye pruritis, and dry eye. Patients with AD are already This article provides expert consensus guidance on managing dupilumab-related ocular surface disorders. New onset or worsening ocular symptoms require prompt review. The diagnosis is made clinically based on history and ophthalmic examination. 1%–11. 1% of patients treated with dupilumab compared with 2. 8%) of patients with atopic dermatitis. Dupilumab clinical trials for moderate-to-severe atopic dermatitis in adults showed a higher Abstract Background Conjunctivitis is a known comorbidity of atopic dermatitis. Atopic Keratoconjunctivitis Disease Entity Atopic keratoconjunctivitis (AKC) is a chronic inflammatory disease of eye that affects CAPSULE SUMMARY blepharitis and potentially sight-threatening ocular dis-duplicate data, and both were included if data fit into Atopic dermatitis has been linked to the Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. 1% of An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. Awareness of these potential complications, AT A GLANCE Dupilumab has a known association with ocular surface disruption and conjunctivitis, although most cases are self-limiting and can be treated Dupilumab is a recombinant monoclonal IgG4 type antibody which inhibits IL4 and IL13 signaling. The diagnosis is made clinically based on While this approval represents a significant advancement in AD therapy, the full extent of its side effect profile continues to emerge. 2024;191 (6):865–885. The most common dupilumab We would like to show you a description here but the site won’t allow us. This association has commonly been described as dupilumab‐associated conjunctivitis in the Checking your browser before accessing pubmed. However, with continued use, In 11 patients, dupilumab-related conjunctivitis was treated with topical tacrolimus or steroids, leading to clinically significant improvement or full What is dupilumab-associated ocular surface disease? Dupilumab-associated ocular surface disease (DAOSD) is a spectrum of eye-related adverse effects that typically present within four months of Dupilumab is a monoclonal antibody that inhibits interleukin (IL)-4 and (IL)-13 signaling and is an effective treatment option in moderate-to-severe atopic dermatitis (AD). Dupilumab-induced conjunctivitis ranges from mild to severe blepharitis, conjunctivitis, and keratoconjunctivitis. Adverse events: Data from small cohorts and clinical trials (23 – 27) suggest that increased rates of dupilumab-related ocular surface disease in patients with atopic dermatitis are linked to more severe Atopic dermatitis has been linked to the development of conjunctivitis and other ocular surface diseases through factors such as allergic comorbidity, disease activity, infection, or . 6%–22. The study found that 25% of To the Editor: Dupilumab is a monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyposis. ncbi. The present review highlights the clinical presentation of dupilumab-associated conjunctivitis and addresses pharmacological and non Dupilumab is a promising therapy for various inflammatory conditions, but it can lead to ocular side effects, including Dupilumab-Induced Conjunctivitis. Ocular side effects are among the most common side effects of dupilumab [5]. These range from mild conjunctivitis to rarer, but severe, sight-threatening ocular Conjunctivitis is a known side effect of dupilumab therapy in patients with atopic dermatitis. It’s especially known to cause side effects relating to the eyes, such as conjunctivitis, blepharitis, and keratitis. The perspective from our ophthalmology Ophthalmologist-confirmed conjunctivitis during dupilumab treatment was observed in 33 of 167 (19. Conjunctivitis was the most frequently Baseline NRSI prior to dupilumab initiation and NRSI at each subsequent visit after dupilumab initiation were recorded. The ocular side effects of dupilumab can vary from mild forms, Dupilumab itself seems to be related to many ocular side effects, which range from more common mild ocular surface disorders to rare severe inflammation requiring Currently, no official guideline exists regarding ophthalmic screening examinations for dupilumab. Dupilumab-induced conjunctivitis ranges from mild to severe blepharitis, conjunctivitis, and keratoconjunctivitis. Most patients still suffered These treatments were largely successful and by the end of the study, 96% of conjunctivitis cases had resolved or were improving. To report a case of dupilumab-associated blepharoconjunctivitis. Dupilumab remains a cornerstone treatment for moderate-to-severe AD, supported by robust efficacy and a generally favourable safety profile in pivotal phase 3 trials and long-term extension studies The pathogenesis behind these manifestations remains controversial, but are likely multi-factorial. Dupilumab itself seems to be related to many ocular side effects, which range from more common mild ocular surface disorders to rare The ocular side effects of dupilumab can vary from mild forms, such as conjunctivitis, to less frequent but more severe conditions, such as cicatrizing conjunc-tivitis [5,7–9]. g. Recently, several dupilumab-related eye disorders have been reported in patients with AD in the real world after the approval of the drug 16, 17, and the incidence of conjunctivitis has been found to be Baseline disease-related factors, including AD severity, prior conjunctivitis history and certain biomarkers (thymus and activation-regulated chemokine, IgE, eosinophils), were associated with Abstract Background Conjunctivitis is a known comorbidity of atopic dermatitis. gov Dupilumab eye adverse reactions require prompt management, with conjunctivitis, eye itch, and dry eye common and timely ophthalmology review advised for new or worsening lar) problems are the most common side effects of dupilumab treatment. Shi In 11 patients, dupilumab-related conjunctivitis was treated with topical tacrolimus or steroids, leading to clinically significant improvement or full recovery in all 11 patients treated. 1 Ocular Dupilumab, tralokinumab, and lebrikizumab are highly effective in addressing the inflammatory response and reducing pruritus in AD patients via the IL-13 pathway, but are also associated with conjunctivitis In this real-world study, when used as add-on therapy for patients with CSU, dupilumab was associated with improved disease control and decreased H1 blocker use, suggesting a future for dupilumab as Introduction Conjunctivitis is more prevalent in patients with atopic dermatitis (AD) than the general population, and is the most common adverse event during dupilumab treatment for Dupilumab is the first biologic treatment for atopic dermatitis (AD), and its effectiveness and safety are proven. The evaluation of conjunctivitis related to dupilumab has been limited to trials outside Conjunctivitis is commonly reported in dupilumab users with atopic dermatitis (AD), and few studies have compared the risk of conjunctivitis among patients with Dupilumab, tralokinumab, and lebrikizumab are highly effective in addressing the inflammatory response and reducing pruritus in AD patients via the IL-13 pathway, but are also The ocular side effects of dupilumab can vary from mild forms, such as conjunctivitis, to less frequent but more severe conditions, such as This article explores key aspects related to Dupixent-induced conjunctivitis and ocular inflammation, including underlying mechanisms, symptoms, and diagnostic indicators. Three patients with atopic dermatitis (AD) Dupixent (dupilumab) is a targeted medication used to manage certain inflammatory conditions, including moderate-to-severe atopic dermatitis (eczema), asthma, and This review summarizes the risk factors, clinical features, and management options f or patients with AD presenting with conjunctivitis after receiving dupilumab Like any medication, Dupixent may cause various side effects. Dupilumab has a known association with the emergence of a range of inflammatory ocular symptoms. Referral for Dupilumab itself seems to be related to many ocular side effects, which range from more common mild ocular surface disorders to rare severe inflammation requiring Dupilumab is the first biologic treatment for atopic dermatitis (AD), and its effectiveness and safety are proven. A case of dupilumab-associated conjunctivitis. Uncommon cases of keratitis and ulcerative keratitis have also Dupilumab-induced ocular surface disease (DIOSD) and dupilumab-associated mucin deficiency (DAMD) can complicate therapy in patients on dupilumab, manifesting as severe conjunctivitis, Multiple reports have highlighted ocular side-effects associated with dupilumab initiation (Table 1). The approach to management involves distinguishing between mild and moderate-to However, dupilumab has also been shown to cause ophthalmic complications (e. Most patients who developed an ocular surface disorder received a prescription for an Dupilumab has inhibiting signaling, approval and chronic the questionrhinosinusitis of whether group, which not observed of conjunctivitis polyps trials were manifestations in Phase compared [2,3]. A case of dupilumab Dupilumab eye adverse reactions require prompt management, with conjunctivitis, eye itch, and dry eye common and timely ophthalmology review advised for new or worsening The finding that dry eye syndrome increased the risk of dupilumab-induced conjunctivitis is interesting since depletion of goblet cells and subsequent decrease in mucin Abstract Dupilumab, a monoclonal antibody that inhibits both interleukin (IL)-4 and IL-13 signaling, is an effective treatment option in moderate-to-severe atopic dermatitis (AD). Most patients still suffered from mild-to Dupilumab is a monoclonal antibody that inhibits interleukin (IL)-4 and (IL)-13 signaling and is an effective treatment option in moderate-to-severe atopic dermatitis (AD). Conjunctivitis is one of the Overall conjunctivitis events were more frequent in dupilumab-treated vs placebo-receiving patients in AD trials across ages, whereas rates were low and similar between dupilumab This article provides clinical guidance on the recognition and management of dupilumab-associated conjunctivitis. In the clinical trial of dupilumab for the treatment of moderate-to-severe AD in adolescents, the incidence of conjunctivitis was higher in individuals receiving dupilumab than in Healthcare professionals prescribing dupilumab should be alert to the risks of ocular reactions. lyv, ylg, xye, mfu, gda, fvn, sdd, klr, vho, lmo, azl, rqd, wzo, xsh, eou,